A phase 1, open label, non-randomized, dose escalation study to evaluate the safety of CP-675,206 in combination with neoadjuvant androgen ablation and a phase 2, open label, randomized study to evaluate the efficacy of CP-675,206 in combination with neoadjuvant androgen ablation and androgen ablation alone in patients with high risk prostate cancer.

Trial Profile

A phase 1, open label, non-randomized, dose escalation study to evaluate the safety of CP-675,206 in combination with neoadjuvant androgen ablation and a phase 2, open label, randomized study to evaluate the efficacy of CP-675,206 in combination with neoadjuvant androgen ablation and androgen ablation alone in patients with high risk prostate cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2012

At a glance

  • Drugs Bicalutamide; Leuprorelin; Tremelimumab
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Sep 2006 Status change
    • 04 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top